1-5 of 5
Thomas Filleron
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Improving Patient Selection for Phase I Trials in Hematology: An External Validation of the Gustave Roussy Scoring System at Toulouse University Cancer Institute, Oncopole (IUCT-O)

Noemie Gadaud, Carlos Gomez Roca, Loic Ysebaert, Aurore Perrot, Myriam Estrabaut, Muriel Poublanc, Iphigenie Korakis, Christian Recher, Jean Pierre Delord, Thomas Filleron, Pierre Bories
Journal: Blood
Blood (2022) 140 (Supplement 1): 5045–5046.
https://doi.org/10.1182/blood-2022-167063
Published: 2022
Journal Articles

TP53 Mutations Negatively Impact Survival of Acute Myeloid Leukemia Patients Treated with Standard Doses of Azacitidine

Pierre Bories, MD, Naïs Prade, Stéphanie Lagarde, Bastien Cabarrou, Julien Plenecassagnes, Isabelle Luquet, MD, Veronique De Mas, Thomas Filleron, PhD, Manon Cassou, Audrey Sarry, Luc Matthieu Fornecker, Célestine Simand, MD, Sarah Bertoli, MD PhD, Hinrich Gronemeyer, Christian Recher, MD PhD, Eric Delabesse, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2745.
https://doi.org/10.1182/blood-2018-99-117219
Published: 2018
Journal Articles

Exome Sequencing Identifies Mecom Missense Variant As Prognostic Marker for Overall Survival of Elderly Acute Myeloid Patients Treated with Azacitidine

Pierre Bories, MD, Naïs Prade, Bastien Cabarrou, Stéphanie Lagarde, Julien Plenecassagnes, Isabelle Luquet, MD, Veronique De Mas, Thomas Filleron, PhD, Manon Cassou, Audrey Sarry, Luc Matthieu Fornecker, Célestine Simand, MD, Sarah Bertoli, MD PhD, Hinrich Gronemeyer, Christian Recher, MD PhD, Eric Delabesse, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1467.
https://doi.org/10.1182/blood-2018-99-117336
Published: 2018
Journal Articles

Immune Recovery Refines the Prognostic Impact of Minimal Residual Disease on Overall and Progression Free Survivals after Frontline Fludarabine, Cyclophosphamide and Rituximab (FCR) in CLL Patients

Martin Gauthier, Florence Durrieu, Michael Peres, MD, Elodie Martin, MSc, Thomas Filleron, PhD, Christian Recher, MD PhD, Anne Quillet Mary, PhD, Loic Ysebaert, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1731.
https://doi.org/10.1182/blood.V130.Suppl_1.1731.1731
Published: 2017
Journal Articles

Efficacy of Chemotherapy or Chemo-Anti-PD-1 Combination after Unsatisfactory Response of Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Retrospective Series from Lysa Centers

Cédric Rossi, MD, Julia Gilhodes, Marie Maerevoet, MD, Charles Herbaux, Pauline Brice, MD, Sylvain Garciaz, Cecile Borel, MD, Loic Ysebaert, MD PhD, Lucie Oberic, MD, Julien Lazarovici, MD, Bénédicte Deau-Fisher, MD, Jehan Dupuis, MD, Adrien Chauchet, Julie Abraham, MD, Fontanet Bijou, Aspasia Stamatoullas-Bastard, Jean Valère Malfuson, Camille Golfier, Camille Laurent, MDPhD, Salim Kanoun, MD, Thomas Filleron, PhD, Rene-Olivier Casasnovas, MD, Hervé Ghesquières, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 652.
https://doi.org/10.1182/blood.V130.Suppl_1.652.652
Published: 2017